You are here: / / / / Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

Publication: Sci Transl Med

Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, Compston A, Johnson AR, Everett C, Bell JI, Karpe F, Ultsch M, Eigenbrot C, McVean G, Fugger L.

2 November 2016

View publication

The NIHR Cambridge BRC is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.

Bluesky

Contact Us

Cambridge Biomedical Research Centre
Box 277
Hills Road
Cambridge
CB2 0QQ

Tel: 01223 348490

Useful Links

About Us
Research
Governance Structure
Partners
Publications
PPIE in Research
News/Events
Vacancies
Accessibility
Privacy

cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
13 Feb

What is #Research #Culture and why should you be interested in it? Why not come along and find out...Thursday 27 February 16.15 - 18.00 ⬇️⬇️
Book Now >> patojomcpeake@thisinstitute.cam.ac.uk
@Cambridge_Uni @CUH_NHS @THIS_Institute

Reply on Twitter 1890067126679163351 Retweet on Twitter 1890067126679163351 Like on Twitter 1890067126679163351 Twitter 1890067126679163351
cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
13 Feb

New #research from Cambridge @Cambridge_Uni shows the need to prioritise #vaccine boosters for those with weakned immune systems to #prevent emergence of new #Covid variants.
@CUH_NHS @NIHRresearch @Gates_Cambridge #vasculitisUK

>> To find out more:

Reply on Twitter 1890034902571339816 Retweet on Twitter 1890034902571339816 2 Like on Twitter 1890034902571339816 6 Twitter 1890034902571339816
cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
12 Feb

Involved in research? Whatever your role/discipline, please spend 15-20 mins filling out a survey https://bit.ly/41aZ69J from @EthicsSciPublicKavli at @Cambridge_Uni on science engagement with the public? @CamUniEngage @engageWCS @StellenboschUni @CUH_NHS

Reply on Twitter 1889650882251284935 Retweet on Twitter 1889650882251284935 2 Like on Twitter 1889650882251284935 3 Twitter 1889650882251284935
cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
11 Feb

Happy #InternationalDayofWomenandGirlsinScience
To commemorate this annual celebration, we interviewed three women from our Cambridge BRC. Look out for Rona Smith's full interview on our website in the coming days..
@CUH_NHS @Cambridge_Uni @NIHRresearch @UNESCO @WomenScienceDay

Reply on Twitter 1889373404295279019 Retweet on Twitter 1889373404295279019 Like on Twitter 1889373404295279019 3 Twitter 1889373404295279019
cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
11 Feb

Happy #InternationalDayofWomenandGirlsinScience
For this global celebration of women in science, we interviewed 3 women from our Cambridge BRC. Look out for Jo McPeake's interview on our website in the coming days
@CUH_NHS @Cambridge_Uni @NIHRresearch @UNESCO @WomenScienceDay

Reply on Twitter 1889372716592963658 Retweet on Twitter 1889372716592963658 1 Like on Twitter 1889372716592963658 5 Twitter 1889372716592963658
cambridgebrc NIHR Cambridge Biomedical Research Centre @cambridgebrc ·
11 Feb

Happy #InternationalDayofWomenandGirlsinScience
To celebrate this global day, we interviewed three women from our Cambridge BRC. Look out for Deborah's full interview on our website in the coming days..
@CUH_NHS @Cambridge_Uni @NIHRresearch @BEARS_CI @UNESCO @WomenScienceDay

Reply on Twitter 1889370490432639371 Retweet on Twitter 1889370490432639371 2 Like on Twitter 1889370490432639371 4 Twitter 1889370490432639371
View more Tweets
© Copyright - NIHR Cambridge Biomedical Research Centre 2025
Assessment of Early Treatment Response to Neoadjuvant Chemotherapy in Breast...Alemtuzumab improves preexisting disability in active relapsing-remitting MS...